https://www.trinitydelta.org/research-notes/ 2026-08-18T16:03:18+00:00 https://www.trinitydelta.org/research-notes/interim-results-show-progress-being-maintained/ 2019-02-21T17:44:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/picking-up-the-pace/ 2019-02-21T23:20:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-insights-from-parkinsons-disease-collaboration/ 2019-02-22T12:05:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/opening-new-pathways-in-immuno-oncology/ 2019-02-23T14:34:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/advancing-towards-randomised-studies/ 2019-02-23T15:17:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/extension-of-clinical-and-commercial-license-with-crispr-therapeutics/ 2019-02-23T15:23:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/arthrex-collaboration-extended-into-europe/ 2019-02-24T17:32:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-strategy-delivering-results/ 2019-02-24T17:37:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-gu-promising-prcc-data-for-savo-durva-combo/ 2019-02-24T18:05:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-certify-study-confirms-ceraments-properties/ 2019-02-24T18:07:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/stronger-commercial-platform-to-make-strategic-inroads/ 2019-02-24T21:05:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/major-milestone-achieved-as-first-patient-is-treated-with-a-carma-product/ 2019-02-24T22:10:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/core-business-continues-to-deliver-as-carma-enters-the-clinic/ 2019-02-24T22:15:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-data-support-potential-in-nsclc/ 2019-02-25T00:07:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/progress-in-all-areas-and-a-longer-cash-runway/ 2019-02-25T08:36:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/missing-out-on-the-cruk-grand-challenge/ 2019-02-25T17:20:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/e-fit-stroke-trial-results-disappoint/ 2019-02-25T23:51:47+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/q218-results-highlight-progress-made-in-the-period/ 2019-02-26T00:19:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/the-defining-inflection-point-expected-within-three-weeks/ 2019-02-26T00:30:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-nbt-system-delivered-in-us-for-major-depression-indication/ 2019-02-26T00:34:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/momentum-building-in-cell-therapy-and-carma/ 2019-03-05T14:42:47+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/executing-the-plan/ 2019-03-05T22:31:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/transitioning-with-growing-confidence/ 2019-03-05T23:15:35+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/setting-the-stage/ 2019-03-06T20:52:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/executing-a-well-articulated-strategy/ 2019-03-06T23:22:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/good-carma-ind-milestone-achieved/ 2019-03-07T11:09:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/biomarkers-point-the-way-ahead/ 2019-03-07T20:22:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/phase-ii-nsclc-combination-study-to-advance-into-second-stage/ 2019-03-07T20:39:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/second-crada-with-the-nih-to-advance-crispr-therapies/ 2019-03-07T21:15:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/another-major-opportunity-arises/ 2019-03-08T16:20:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/parkinsons-disease-collaboration-with-c4x-discovery/ 2019-03-08T17:34:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/capital-raised-as-new-opportunities-open-up/ 2019-03-08T17:51:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/another-year-of-strong-delivery-as-carma-approaches-the-clinic/ 2019-03-08T18:00:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-lean-and-mean-drug-discovery-machine/ 2019-03-08T18:08:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/recruitment-to-first-stage-of-tnbc-phase-ii-completed-ahead-of-schedule/ 2019-03-08T19:12:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/funded-to-achieve-multiple-value-inflection-points/ 2019-03-08T19:37:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/promising-first-clinical-data-in-immuno-oncology/ 2019-03-08T20:05:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/initial-clinical-i-o-data-for-bemcentinib-bgb324-is-promising/ 2019-03-08T20:11:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-carma-therapy-to-enter-clinic-in-2018/ 2019-03-08T20:39:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strengthening-the-platform-through-collaboration/ 2019-03-08T20:45:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/good-progress-as-first-commercial-deal-sought/ 2019-03-08T21:58:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-rosy-outlook-for-axl/ 2019-03-09T00:25:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/no-smoke-but-plenty-of-fire/ 2019-03-09T17:51:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/executing-the-strategy/ 2019-03-09T18:01:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/reaping-continued-returns-from-rd/ 2019-03-09T18:11:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/refining-its-focus/ 2019-03-09T18:15:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/consolidating-its-leadership/ 2019-03-09T18:17:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/advancing-impressively-on-all-fronts/ 2019-03-10T20:29:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/resolution-of-rigel-arbitration-reduces-uncertainty/ 2019-03-11T23:41:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/getting-re-energised/ 2019-03-12T00:01:38+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/unshackling-itself-from-its-bonds/ 2019-03-12T23:45:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/another-quarter-of-delivery/ 2019-03-13T00:05:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/funding-to-support-proxima-4-roll-out-being-finalised/ 2019-03-13T00:13:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercialisation-is-underway/ 2019-03-13T10:39:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/2016-results-highlight-the-progress-achieved/ 2019-03-13T15:55:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercialisation-now-begins/ 2019-03-13T16:04:04+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/on-the-cusp-of-commercialisation/ 2019-03-13T20:25:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-belgian-order-for-proxima-confirmed/ 2019-03-13T20:39:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ce-mark-expected-shortly-launch-preparations-on-track/ 2019-03-13T20:45:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/worthy-of-further-evaluation/ 2019-03-13T21:30:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/global-aspirations-for-a-top-class-chinese-innovator/ 2019-03-14T16:23:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/creating-the-right-conditions-for-future-growth/ 2019-03-14T16:27:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/entering-the-next-stimulating-phase/ 2019-03-14T16:29:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/growing-us-cerament-bvf-in-market-sales/ 2019-03-14T16:33:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/more-than-just-bridging-a-gap/ 2019-03-14T16:37:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/securing-the-commercial-future-of-nbt-in-depression/ 2019-03-18T13:37:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/achieving-commendable-outcomes-in-depression/ 2019-03-21T14:47:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-commercial-deal-secured-with-global-diabetes-leader/ 2019-03-21T14:52:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/navigating-the-opportunity-in-depression/ 2019-03-21T14:54:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/putting-more-flesh-on-the-bones/ 2019-03-21T14:56:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/the-corner-has-been-turned/ 2019-03-21T15:08:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/portfolio-progress-validates-investment-philosophy/ 2019-03-21T15:09:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/entering-an-important-year/ 2019-03-21T15:15:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/positive-news-flow-drives-valuation-uplift/ 2019-03-21T15:18:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/portfolio-companies-delivering-as-planned/ 2019-03-21T15:21:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/e-therapeutics-initiation-270617/ 2019-03-21T15:24:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/setting-the-scene-for-a-significant-shift/ 2019-03-21T15:28:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-year-to-remember/ 2019-03-21T15:30:57+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/maiden-commercial-deal-announced-for-use-in-crispr/ 2019-03-21T15:32:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/gearing-up-the-growth/ 2019-03-21T15:35:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/advancing-across-all-fronts/ 2019-03-21T15:38:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ce-mark-opens-the-door-to-commercialisation/ 2019-03-21T15:41:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/terms-of-the-rights-issue-announced/ 2019-03-28T09:08:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/further-support-for-bemcentinibs-broad-potential-from-preclinical-data-at-aacr/ 2019-04-01T14:53:38+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/efficacy-endpoint-met-in-phase-ii-aml-study/ 2019-04-02T06:30:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/bringing-global-innovation-and-china-oncology-into-focus/ 2019-04-09T08:34:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/aacr-2019-savolitinib-in-the-spotlight-in-nsclc/ 2019-04-09T11:00:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy18-results-as-expected-plentiful-news-flow-in-fy19/ 2019-04-15T22:13:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/path-cleared-for-partnering-of-acumapimod-bct-197/ 2019-04-16T06:07:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/capital-raised-to-advance-carma-primarily/ 2019-04-18T13:53:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/phase-ii-melanoma-study-with-scib1-to-start-in-q219/ 2019-04-25T13:42:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/gearing-up-for-growth/ 2019-05-03T14:03:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at-the-forefront-of-the-cell-therapy-revolution/ 2019-05-03T14:04:15+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-momentum/ 2019-05-07T13:00:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/dosing-advances-to-second-cohort-in-carma-phase-i/ 2019-05-08T08:43:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/focus-shifts-back-to-imminent-data/ 2019-05-08T11:35:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scib2-to-use-new-nanoparticle-formulation/ 2019-05-20T14:25:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/getting-back-on-the-front-foot/ 2019-05-21T11:38:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/encouraging-interim-bps-804-data-in-oi/ 2019-05-31T07:13:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/axl-ready-to-turn-another-revolution/ 2019-05-31T16:19:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/vulpes-investment-brings-3-88m-in-new-funds/ 2019-06-13T10:14:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/timing-is-right-for-a-hong-kong-debut/ 2019-06-18T09:35:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/surufatinib-on-track-for-potential-2020-china-approval/ 2019-06-18T10:40:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-more-supportive-data-for-bemcentinib/ 2019-06-19T00:06:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/private-placement-to-support-randomised-phase-ii-trials/ 2019-06-19T06:40:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ground-prepared-for-an-important-period/ 2019-07-01T10:36:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/accelerated-approval-path-for-navi/ 2019-07-16T07:57:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ideally-placed-to-sustain-growth/ 2019-07-17T06:29:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/all-eyes-on-q3-following-a-record-q2/ 2019-08-01T14:13:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/carrying-momentum-into-h219/ 2019-08-13T11:37:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/second-agreement-helps-validate-capabilities/ 2019-08-13T12:07:36+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/refining-the-route-ahead/ 2019-08-20T07:48:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/promising-progress-with-nbt/ 2019-08-20T12:40:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-sweet-source-of-financing/ 2019-09-04T11:10:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scib1-phase-ii-study-starts-in-uk/ 2019-09-04T11:11:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/impressive-data-means-sanet-ep-trial-stopped-early/ 2019-09-09T13:16:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/secondary-ads-offering-trims-ck-hutchison-stake/ 2019-09-09T13:53:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/proposed-listing-in-hong-kong-and-global-offering/ 2019-09-09T13:56:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/voluntary-loan-repayments-remove-kreos-uncertainty/ 2019-09-17T08:23:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/consistent-solid-delivery/ 2019-09-19T12:08:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/entering-an-important-12-month-period/ 2019-09-19T13:57:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/wclc-2019-detailed-faluca-data-disclosed/ 2019-09-26T14:50:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/esmo-2019-surufatinib-epnet-pfs-benefit-confirmed/ 2019-10-03T10:50:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/editas-deal-marks-sixth-commercial-licence/ 2019-10-07T08:23:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-possible-new-opportunity-in-severe-depression/ 2019-10-09T08:32:17+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/q319-update-shows-therapy-business-momentum/ 2019-10-16T11:11:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/warrants-to-be-topped-up-with-share-placement/ 2019-10-22T10:46:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/third-cohort-in-carma-phase-i-initiated/ 2019-10-24T06:30:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/acceptance-of-surufatintib-china-nda-in-epnet/ 2019-11-12T11:59:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-second-consecutive-quarter-of-record-revenue/ 2019-11-18T12:45:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/setrusumab-set-to-advance/ 2019-11-18T13:16:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/bemcentinib-nsclc-data-continues-to-impress/ 2019-11-19T13:53:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/and-yet-another-commercial-licence-agreement/ 2019-11-21T09:02:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/elegant-and-effective-treatment-for-erectile-dysfunction/ 2019-11-25T09:26:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/setrusumab-ready-to-advance-into-pivotal-studies/ 2019-11-25T11:59:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/elunate-fruquintinib-secures-china-nrdl-listing/ 2019-11-29T11:56:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercial-licence-agreement-with-ksq/ 2019-12-04T07:08:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/are-these-unprecedented-results-a-major-opportunity/ 2019-12-10T12:52:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ash-data-continues-to-support-aml-potential/ 2019-12-10T13:33:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/remarkable-data-from-pivotal-trial-opens-new-possibilities/ 2019-12-11T09:56:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/second-collaboration-for-avidimab-platform/ 2019-12-16T12:08:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/making-an-impression-in-depression/ 2020-01-07T09:12:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/underappreciated-and-undervalued/ 2020-01-07T10:50:17+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/axl-opportunities-opening-up/ 2020-01-08T11:32:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/oncologie-takes-global-licence-to-navi/ 2020-01-13T14:30:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/additional-asteroid-data-supports-progression/ 2020-01-15T16:41:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/licensing-discussions-with-academic-centre-end/ 2020-01-17T12:34:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/increasingly-in-demand-as-partner-of-choice/ 2020-01-20T08:54:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/third-collaboration-for-avidimab-platform/ 2020-01-20T11:03:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fund-raise-of-3-25m-at-8p-a-share-confirmed-at-egm/ 2020-01-21T09:38:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/sanet-p-trial-stopped-early-for-efficacy/ 2020-01-21T09:59:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/110m-raised-through-ads-public-offer/ 2020-01-23T12:01:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/2020-set-to-be-the-breakthrough-year/ 2020-01-27T10:32:38+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/interim-results-show-encouraging-progress/ 2020-01-31T11:49:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/us-ind-for-scib1-gives-phase-ii-study-the-green-light/ 2020-02-03T14:31:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/focused-on-second-line-nsclc-and-aml/ 2020-02-12T09:46:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-european-regulatory-pathway-is-clearer/ 2020-02-17T08:40:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-wealth-of-opportunity-for-surufatinib/ 2020-02-18T17:07:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/cementing-the-foundations-for-growth/ 2020-03-02T08:55:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/focussing-on-strategic-priorities/ 2020-03-02T08:55:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/progress-suggests-that-2020-will-be-a-decisive-year/ 2020-03-04T11:48:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/accelerated-fda-pathway-for-cerament-g/ 2020-03-23T15:30:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/encouraging-fy19-results-and-med3000-update/ 2020-04-01T09:03:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-more-detail-on-fm57-results/ 2020-04-02T06:56:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/patient-registry-shows-promising-outcomes-in-mdd/ 2020-04-20T06:46:13+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/top-cancer-advanced-therapy-company-partnership/ 2020-04-20T19:23:15+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy19-results-crown-a-breakthrough-year/ 2020-04-21T06:46:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/bemcentinib-fast-tracked-into-covid-19-trial/ 2020-04-30T10:07:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/e2-3m-rights-issue-to-progress-both-nbs-and-nbt/ 2020-05-04T07:04:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/25-1m-31-0m-successully-raised/ 2020-05-05T06:59:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/nok500m-raised-to-drive-bemcentinib-progress/ 2020-05-05T08:33:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/crispr-cas9-gene-editing-pioneer-secures-licence/ 2020-05-07T06:25:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/reasons-to-be-cheerful/ 2020-05-11T09:29:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/covid-2nd-generation-vaccine-opportunity-is-all-upside/ 2020-05-11T10:44:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/hitting-the-right-spot/ 2020-05-22T13:35:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/enabling-cell-therapies-to-progress/ 2020-05-26T06:54:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/sek-378m-raised-through-directed-share-issue/ 2020-05-28T06:45:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-poster-shows-encouraging-data-for-mcy-m11/ 2020-06-02T06:46:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/nearing-the-critical-point-in-erectile-dysfunction/ 2020-06-02T06:50:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/e2-3m-rights-issue-is-273-subscribed/ 2020-06-02T12:30:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/private-placement-raises-70m-56m/ 2020-06-04T10:12:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/funding-deals-worth-up-to-33m-announced/ 2020-06-04T12:58:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/general-atlantic-invests-100m-at-10-premium/ 2020-06-25T11:21:13+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/swings-and-roundabouts/ 2020-06-29T07:08:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/axl-erating-towards-new-opportunities/ 2020-06-29T08:17:47+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/agm-statement-confirms-med3000-filings-on-track/ 2020-07-13T19:27:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fda-green-lights-med3000-for-otc-approval/ 2020-07-14T09:23:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/apeiron-licence-broadens-the-maxcyte-opportunity/ 2020-07-14T18:54:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-products-new-deals-attractive-prospects/ 2020-07-15T06:59:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/material-fund-raise-means-clinical-progress-in-sight/ 2020-07-22T08:20:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/laying-the-foundations-for-a-new-era/ 2020-08-06T12:07:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/weathering-the-covid-19-storm/ 2020-08-06T12:09:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-2020-savo-and-suru-data-drives-regulatory-progress/ 2020-08-06T12:16:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/aacr-2020-first-surufatinib-pd-1-combo-data/ 2020-08-06T12:21:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/innovative-pipeline-closer-to-realising-its-potential/ 2020-08-10T10:26:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/transformational-15m-capital-raise-closes/ 2020-08-12T06:38:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/broadened-scope-for-current-mcy-m11-phase-i-study/ 2020-08-18T06:45:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/mapping-out-the-2020-24-corporate-strategy/ 2020-08-18T06:50:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/tigit-programme-starts-the-next-chapter/ 2020-09-02T06:53:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-on-course-for-otc-approval-in-europe-and-us/ 2020-09-16T08:23:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/esmo-2020-sanet-p-delivers-further-positive-suru-data/ 2020-09-22T13:38:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strong-performances-against-strategic-goals/ 2020-09-23T06:46:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/in-the-vanguard-of-next-generation-cell-and-gene-therapies/ 2020-10-06T09:04:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ukri-awards-funding-for-covid-19-trial/ 2020-10-12T10:05:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h120-results-and-corporate-review/ 2020-10-12T10:59:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/redmile-endorses-technologies-with-a-further-30m/ 2020-10-16T14:03:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-fda-details-the-scope-of-confirmatory-study/ 2020-10-22T07:14:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/innovative-g309-exploratory-grass-trial-starts/ 2020-10-26T13:46:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/redmile-funding-releases-the-brakes/ 2020-11-17T09:08:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/canada-pension-plan-invests-100m-at-30-per-ads/ 2020-11-17T13:34:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/pilot-studies-lift-off-in-depression-and-pain/ 2020-11-18T12:28:04+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/e0-9m-prototype-research-project-signed/ 2020-11-18T12:43:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/25-5m-placing-extends-runway-to-end-2022/ 2020-12-02T11:41:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/targeting-tigit-thoughtfully/ 2020-12-09T11:59:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/raring-to-go-in-rare-diseases/ 2020-12-18T10:09:36+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/phase-ii-starts-with-backing-from-patient-support-group/ 2020-12-18T10:10:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/merger-with-nasdaq-listed-oncomed/ 2020-12-18T10:11:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/setrusumab-partnered-with-ultragenyx/ 2020-12-18T11:55:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/proof-is-in-the-pipeline/ 2020-12-22T12:28:47+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/funding-secured-to-support-next-chapter-of-growth/ 2021-01-04T09:40:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/china-approval-clears-sulanda-in-epnet/ 2021-01-04T16:40:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/imperial-peanut-allergy-biomarker-study-underway/ 2021-01-05T07:49:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/robust-growth-pipeline-progress-and-cash-position/ 2021-01-13T07:53:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy20-results-highlight-extent-of-progress-made/ 2021-01-27T08:02:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h121-results-highlight-shift-to-delivery-and-execution/ 2021-01-29T08:00:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/us-institutional-private-placing-raises-40m/ 2021-02-05T08:07:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/better-visibility-brings-future-into-focus/ 2021-02-08T15:06:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/promising-results-for-severe-depression-pilot-study/ 2021-03-03T12:34:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-positive-start-to-the-2020-24-strategy/ 2021-03-04T07:40:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercialisation-deal-for-china-and-se-asia/ 2021-03-04T09:21:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/transitioning-to-a-global-oncology-player/ 2021-03-05T13:39:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/subscription-rights-issue-of-e6-6m-at-e0-03-per-share/ 2021-03-08T14:23:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/record-revenues-demonstrate-resilience-of-operations/ 2021-03-15T22:40:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/eu-notified-body-recommends-med3000-approval/ 2021-03-19T09:04:36+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/breaking-new-ground-in-china-and-globally/ 2021-04-07T15:31:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rights-issue-178-oversubscribed/ 2021-04-08T08:12:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/baring-private-equity-asia-invests-100m/ 2021-04-08T14:11:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-is-set-to-be-a-year-of-execution/ 2021-04-14T08:01:47+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-receives-ce-mark-as-a-class-iib-device/ 2021-04-30T07:16:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/g309-exploratory-grass-trial-on-course-for-h221-read-out/ 2021-05-06T08:10:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/parsortix-commercial-traction-would-be-transformational/ 2021-05-11T06:55:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/consolidating-both-shares-and-strategy/ 2021-05-12T09:22:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/raising-12m-through-10m-placing-and-2m-retail-offer/ 2021-05-17T08:04:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/momentum-and-execution-continue-in-h121/ 2021-06-08T12:28:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/receipt-of-4m-milestone-for-rxc006-progress/ 2021-06-17T13:14:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/%e2%89%a5600m-hong-kong-ipo-and-global-offer-104m-shares/ 2021-06-21T07:17:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/covidity-programme-to-start-phase-i-in-h221/ 2021-06-22T09:20:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-pre-close-update-ahead-of-market-expectations/ 2021-06-24T07:01:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/20m-placing-to-accelerate-parsortix-opportunities/ 2021-06-28T10:16:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/hong-kong-listing-number-13-is-a-potent-symbol/ 2021-07-06T10:49:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-2021-moving-towards-combinations/ 2021-07-06T11:11:57+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/planning-the-next-phase-of-growth/ 2021-07-08T08:29:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strong-fy21-trading-but-pipeline-set-to-drive-future/ 2021-07-14T06:45:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rezurock-approval-has-positive-read-across-for-redx/ 2021-07-19T07:11:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rxc004-2mg-dose-selected-for-phase-ii-trials/ 2021-07-27T14:37:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-custom-ctc-assay-development-contract/ 2021-07-29T07:01:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/catching-an-unbroken-wave/ 2021-07-30T07:09:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/cta-approval-confirms-h221-covidity-phase-i-start/ 2021-07-30T09:44:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/biomarker-data-confirm-vlp-peanut-hypoallergenicity/ 2021-08-03T06:38:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strategic-collaboration-for-tazverik-in-greater-china/ 2021-08-10T10:55:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/lead-therapeutic-asset-ava6000-enters-the-clinic/ 2021-08-11T13:07:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/accelerated-protocols-could-be-a-game-changer/ 2021-08-19T06:44:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/all-that-jazz-3m-milestone-boosts-cash-and-confidence/ 2021-09-07T06:56:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/so-much-more-than-a-play-on-covid-testing/ 2021-09-09T14:29:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/formulating-the-recipe-for-success/ 2021-09-14T06:28:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at278-phase-i-delivers-better-than-expected-results/ 2021-09-20T10:19:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/vlp-peanut-heading-towards-us-phase-i-studies/ 2021-09-21T10:12:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/esmo-2021-rxc004-monotherapy-phase-i-study-results/ 2021-09-21T19:24:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h121-results-underline-quality-of-management-execution/ 2021-09-23T06:42:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-results-show-continued-strong-growth/ 2021-09-23T06:57:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-year-of-delivery-with-key-milestones-achieved/ 2021-09-30T09:16:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/poised-to-disrupt-existing-tumour-assay-protocols/ 2021-10-01T06:55:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/kadmon-acquisition-has-read-across-for-rxc007/ 2021-10-11T16:51:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rd-update-rxc004-and-rxc007-in-the-spotlight/ 2021-10-12T09:18:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/nkarta-signs-spl-to-accelerate-its-nk-cell-therapies/ 2021-11-04T08:38:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/foundations-for-two-healthy-businesses-now-in-place/ 2021-11-29T09:25:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ava6000-set-to-start-us-phase-i-studies-in-early-2022/ 2021-11-29T09:40:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/management-update-details-degree-of-2021-progress/ 2021-12-20T11:00:13+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/consumer-testing-ce-mark-received-for-affidx-lft/ 2021-12-22T09:56:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/affidx-lft-sales-paused-to-improve-omicron-detection/ 2022-01-10T13:04:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/admirable-execution-on-2021-strategic-goals/ 2022-01-12T07:43:38+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercialising-and-developing-a-differentiated-portfolio/ 2022-01-13T08:01:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/formulation-expertise-exemplified-in-diabetes/ 2022-01-20T08:15:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/positive-top-line-g309-results-for-grass-mata-mpl/ 2022-01-25T18:19:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fda-green-lights-vlp-peanut-vaccine-phase-i-trial/ 2022-01-26T08:10:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-results-a-year-of-continuing-delivery/ 2022-01-27T10:09:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-on-an-impressive-track-record/ 2022-02-17T07:51:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-steps-on-path-towards-longer-term-profitability/ 2022-03-02T07:47:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/solid-commercial-performance-with-major-rd-upside/ 2022-03-03T07:41:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-genuinely-global-rd-driven-biopharma-business/ 2022-03-03T15:58:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/opening-the-next-chapter/ 2022-03-09T08:04:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/menarini-to-commercialise-med3000-in-south-korea/ 2022-03-23T08:58:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rxc008-nominated-as-gi-rock-drug-candidate/ 2022-03-30T08:11:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-results-a-year-of-frustrations-and-opportunities/ 2022-04-06T07:04:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/sustained-fy21-growth-with-significantly-more-potential/ 2022-04-06T07:53:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-fresh-impetus-in-delivering-immune-oncology-vaccines/ 2022-04-12T07:04:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ambitious-focussed-and-delivering-on-its-promise/ 2022-04-25T14:01:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-results-reassure-on-cash-runway-and-hint-at-eu-deal/ 2022-04-26T06:24:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/robust-cell-therapy-performance-lifts-fy22-guidance/ 2022-05-23T06:17:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/major-med3000-deal-for-europe-with-cooper-health/ 2022-05-23T06:17:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at278-hits-the-sweet-spot/ 2022-05-31T08:54:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/34-3m-raise-extends-runway-through-key-data-points/ 2022-06-07T07:28:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-moditope-oncology-vaccine-enters-the-clinic/ 2022-06-13T09:54:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/jazz-pharmaceuticals-5m-milestone-triggered/ 2022-06-15T11:12:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/all-the-ingredients-for-success-now-in-place/ 2022-06-29T06:20:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ava6000-set-for-third-dose-escalation-stage/ 2022-06-30T06:21:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-data-on-track-return-to-growth-expected-next-year/ 2022-07-15T07:03:54+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/acquisition-of-tetris-pharma-and-6m-equity-raise/ 2022-08-01T11:20:17+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/right-here-right-now-catching-the-car-t-wave/ 2022-08-11T10:54:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/from-strength-to-strength-with-carma-expansion/ 2022-08-11T13:05:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strategic-investments-to-support-partners-future-growth/ 2022-09-06T11:42:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-clinical-diabetes-events-on-track-for-h222/ 2022-09-08T07:39:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fm71-achieves-all-primary-and-secondary-endpoints/ 2022-09-13T06:26:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/interims-highlight-positive-first-signs-in-key-markets/ 2022-09-13T06:31:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/broadening-opportunities-and-preparing-for-the-future/ 2022-09-21T16:27:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-tx-and-dx-portfolios-from-proprietary-platforms/ 2022-09-29T09:07:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/vertex-pharmaceuticals-secures-exa-cel-spl/ 2022-09-29T09:11:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/on-the-starting-blocks-towards-key-data-expected-in-2023/ 2022-09-29T09:13:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-data-draws-attention-to-promising-fibrosis-assets/ 2022-10-07T07:24:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/diagnostics-ma-led-growth-strategy-is-ready-to-launch/ 2022-10-18T12:01:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/optimum-partner-secured-for-first-antibody-deal/ 2022-10-25T07:12:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/manufacturing-pause-takes-it-toll-on-revenues/ 2022-10-28T06:21:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy22-results-highlight-clinical-and-corporate-progress/ 2022-10-28T10:33:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at247-phase-i-pump-data-confirms-promising-profile/ 2022-11-09T21:42:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/on-the-cusp-of-med3000-commercialisation/ 2022-11-10T07:06:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/specialty-hospital-products-formulation-collaboration/ 2022-11-10T09:42:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fruquintinib-should-continue-to-bear-fruit/ 2022-11-21T07:43:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-sharper-focus-on-the-path-to-profitability/ 2022-11-21T12:04:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/start-of-pivotal-grass-mata-mpl-phase-iii-trial/ 2022-12-08T09:14:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-continues-to-progress-towards-first-sales/ 2022-12-13T07:28:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/diagnostics-business-back-into-the-spotlight/ 2022-12-13T08:22:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-steps-towards-fruquintinib-availability-in-the-us/ 2022-12-20T07:24:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/getting-the-chemistry-right/ 2022-12-20T07:55:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/laying-the-foundations-for-further-delivery-in-2023/ 2022-12-21T14:31:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/annual-report-and-accounts-delayed-shares-suspended/ 2022-12-29T14:35:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/hikma-licence-milestone-achieved/ 2023-01-13T08:10:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ava6000-shows-signs-of-successful-tumour-targetting/ 2023-01-17T10:04:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/takeda-licenses-fruquintinib-in-1-13bn-ex-china-deal/ 2023-01-24T07:51:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-phase-ii-data-for-lead-assets-expected-during-h223/ 2023-01-30T08:16:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rxc007-recruitment-scales-up-data-now-q124/ 2023-02-09T10:11:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-leader-in-antibody-and-vaccine-oncology-platforms/ 2023-02-15T07:59:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/modi-1-successful-in-first-part-of-phase-i-ii-trial/ 2023-02-21T07:30:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/recommended-all-share-combination-with-jounce/ 2023-03-01T10:27:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/delivering-commercially-and-strategically-during-fy22/ 2023-03-02T16:00:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/004-mono-insufficient-in-btc-h223-combo-is-key/ 2023-03-08T15:47:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-soft-launch-in-europe-fda-approval-now-q2/ 2023-03-14T12:13:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fundamentals-intact-with-catalysts-on-the-horizon/ 2023-04-04T08:33:28+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/gearing-up-for-further-launches-in-2023/ 2023-04-05T07:01:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy22-results-point-to-progress-across-tx-and-dx/ 2023-04-25T07:37:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rock-solid-start-in-cancer-associated-fibrosis/ 2023-05-11T08:01:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/two-key-phase-ii-results-on-track-for-next-12-months/ 2023-05-18T11:18:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/diagnostics-build-out-continues-with-coris-acquisition/ 2023-06-01T10:53:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-on-therapeutic-and-diagnostic-foundations/ 2023-06-02T08:30:15+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/med3000-fda-clearance-marks-a-major-step-in-the-us/ 2023-06-12T09:03:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/first-months-of-eroxon-launch-suggest-a-successful-start/ 2023-06-22T06:32:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-takeaways-from-investor-seminar/ 2023-06-26T06:28:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/haleon-to-commercialise-med3000-in-the-us/ 2023-07-17T06:18:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/continued-delivery-with-key-at278-data-due-in-q423/ 2023-07-19T19:39:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/pipeline-and-partnership-progress-plus-upcoming-catalysts/ 2023-07-20T08:28:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/delivering-on-sharpened-goals-and-priorities/ 2023-08-01T10:55:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/upcoming-scib1-data-could-provide-first-proof-of-concept/ 2023-09-05T06:19:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/growth-plans-starting-to-stack-up/ 2023-09-14T07:21:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/significant-achievements-position-med3000-for-success/ 2023-09-18T06:30:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scib1-scope-study-shows-a-striking-82-orr/ 2023-09-19T06:14:38+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/momentum-builds-in-diagnostics-and-therapeutics/ 2023-09-28T06:08:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-funds-provide-runway-through-2024-catalysts/ 2023-10-18T06:06:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/business-update-and-fy23-results/ 2023-10-31T07:11:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/landmark-fda-approval-for-fruquintinib/ 2023-11-13T07:09:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at220-european-launch-marks-first-arestat-success/ 2023-11-17T07:22:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/appreciating-a-well-executed-development-strategy/ 2023-11-30T11:57:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/successful-upsized-placing-raises-over-10m/ 2023-12-01T07:32:24+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/second-in-house-specialty-hospital-deal/ 2023-12-07T06:59:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/tailored-tumour-targetting-with-precision/ 2023-12-14T11:25:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/sanofi-deal-for-inbrx-101-validates-arestat-technology/ 2024-01-24T07:11:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/heading-into-important-2024-clinical-catalysts/ 2024-01-31T07:05:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-deals-and-first-royalties-to-aid-growth-key-data-h124/ 2024-02-01T09:26:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/eroxon-continues-to-build-further-new-launches-expected/ 2024-02-06T08:23:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/up-to-870m-kras-deal-marks-third-jazz-collaboration/ 2024-02-07T07:17:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fruquintinib-clinical-and-commercial-updates/ 2024-02-12T10:33:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/anticipating-clinical-momentum-and-catalysts-in-2024/ 2024-02-27T14:25:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ready-to-rock-as-rxc008-enters-the-clinic/ 2024-02-28T07:22:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy23-results-point-to-strong-financials-and-fundamentals/ 2024-02-29T09:17:32+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/successful-31-1m-fundraise-despite-challenging-markets/ 2024-03-06T07:26:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/trx-co-development-deal-centred-on-oral-glp-1-product/ 2024-03-13T07:42:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/voluntary-delisting-from-aim-to-go-private/ 2024-04-02T06:28:04+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/profitability-in-sight-as-partner-preps-for-us-launch/ 2024-04-10T06:19:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/aacr-data-continue-to-support-confidence-in-ava6000/ 2024-04-10T07:15:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/eroxon-poised-for-launch-in-key-us-market/ 2024-04-25T07:26:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/therapeutics-focus-sharpening-cash-to-key-catalysts/ 2024-04-30T09:50:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/novel-diabetes-drug-device-deal-inked-with-medtronic/ 2024-05-09T06:27:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strong-us-fruzaqla-q1-eu-approval-could-come-soon/ 2024-05-13T10:59:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy23-results-evidence-broader-revenue-base/ 2024-05-16T06:18:33+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at278-ultra-concentrated-insulin-superior-to-benchmarks/ 2024-05-20T08:46:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/data-and-clinical-progress-validate-precision-platform/ 2024-06-06T06:14:09+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/glymab-evaluation-agreement-with-major-biotech-player/ 2024-06-13T06:15:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/focus-remains-firmly-on-fibrosis-and-related-diseases/ 2024-07-10T07:32:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rd-day-highlights-prospects-for-key-late-stage-products/ 2024-07-11T06:53:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/funding-growth-diabetes-still-the-key-value-driver/ 2024-07-23T06:22:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/haleon-confirms-us-eroxon-launch-by-end-2024/ 2024-08-01T06:22:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/continued-h124-execution-well-on-track-to-meet-targets/ 2024-08-02T06:38:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/maiden-h1-profit-fy-profit-expected-with-q3-us-launch/ 2024-09-10T06:05:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/earlier-us-eroxon-launch-brings-forward-profitability/ 2024-09-11T11:27:17+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/easd-2024-positive-phase-i-for-at278-in-type-ii-diabetes/ 2024-09-17T06:12:42+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/esmo-24-compelling-data-for-ava6000-and-precision/ 2024-09-17T14:02:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy24-cash-to-deliver-on-key-clinical-catalysts/ 2024-09-24T06:14:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h124-focus-on-next-steps-for-diabetes-and-obesity/ 2024-09-26T06:23:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h124-interims-a-time-to-reflect-on-progress-achieved/ 2024-09-30T13:59:26+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scope-readouts-in-sight-scib1-data-in-q424/ 2024-10-17T06:29:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/next-gen-precision-data-unveiled-at-triple-meeting/ 2024-10-24T13:25:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/cohort-1-scope-data-confirms-scib1-response-rates/ 2024-11-18T07:16:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/genmab-strikes-second-glymab-deal/ 2024-12-04T10:35:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fundraise-extends-cash-into-h226-beyond-key-catalysts/ 2024-12-06T08:13:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ash-2024-long-term-data-show-sovleplenib-benefit/ 2024-12-09T12:16:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-licence-adds-at351-to-partnered-pipeline/ 2025-01-06T07:28:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/tetris-pharma-to-be-wound-down-ogluo-rights-returned/ 2025-01-10T07:49:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/poised-for-several-pivotal-clinical-events-in-2025/ 2025-01-13T09:23:07+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/home-use-study-supports-wsd4000-development/ 2025-01-15T07:23:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h125-reaffirms-funds-are-sufficient-to-deliver-key-data/ 2025-01-30T07:09:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy25-revenues-to-be-materially-below-expectations/ 2025-01-30T07:44:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at278-co-development-deal-in-advanced-discussions/ 2025-02-04T15:22:22+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/at220-sales-building-momentum/ 2025-03-04T16:27:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ 2025-03-04T16:30:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/executing-steadily-on-therapeutics-focused-strategy/ 2025-03-18T07:04:35+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/profitability-milestone-achieved-ahead-of-schedule/ 2025-03-20T07:12:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/innovating-and-adapting-in-a-new-product-category/ 2025-04-22T06:16:08+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/sachi-details-de-risk-savolitinib-potential-approvals/ 2025-06-05T11:01:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy24-shift-to-pure-play-biopharma-nears-completion/ 2025-06-11T06:04:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/cancer-vaccine-data-due-soon-glymab-developments-too/ 2025-06-25T07:20:37+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/beneath-the-tip-of-the-precision-iceberg/ 2025-06-26T06:39:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fundraise-of-7m-provides-much-needed-cash/ 2025-06-30T16:07:04+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/commercialising-cutting-edge-diagnostics/ 2025-06-30T16:08:14+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/seeking-deals-to-enhance-episwitch-revenue-potential/ 2025-06-30T16:09:12+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h125-working-towards-delivering-on-objectives/ 2025-07-01T06:05:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/orpathys-tagrisso-combination-approved-in-china/ 2025-07-01T07:27:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/key-immunobody-clinical-data-imminent/ 2025-07-09T06:24:01+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/successful-scope-outcome-and-iscib1-selection/ 2025-07-22T06:25:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scopeing-out-iscib1-in-advanced-melanoma/ 2025-08-04T06:17:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h125-growth-prospects-remain-intact/ 2025-08-07T15:18:52+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/cb-amendment-creates-funding-solution-optionality/ 2025-09-01T14:30:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/prowes-cirt-utility-in-guiding-treatment-decisions/ 2025-09-05T06:27:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy25-full-steam-ahead-with-iscib1/ 2025-09-11T06:23:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/kkey-faridox-data-and-fap-exd-phase-i-start-on-the-horizon/ 2025-10-08T08:40:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/new-episwitch-test-for-chronic-fatigue-syndrome/ 2025-10-10T07:44:56+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/esmo-fruquintinibs-significant-benefit-in-kidney-cancer/ 2025-10-14T07:25:46+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/dual-payload-precision-unveiled-at-eortc-nci-aacr/ 2025-10-14T10:35:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fap-dox-cardiotox-impresses-crucial-16m-fundraise/ 2025-10-20T10:13:58+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/7m-fundraise-secures-near-term-future/ 2025-10-22T10:56:55+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h125-pharma-services-focus-attenuates-industry-headwinds/ 2025-10-30T10:07:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/priming-the-pharma-services-market/ 2025-10-30T10:09:03+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-a-pharma-partnership-pipeline-and-medtech-too/ 2025-10-30T10:09:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/assays-complete-for-astrazeneca-utility-of-her2-demoed/ 2025-10-30T10:09:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-fuller-picture-from-dual-ctc-dna-and-ctdna-analysis/ 2025-10-30T10:09:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/adapting-to-align-with-the-biggest-future-opportunities/ 2025-10-30T10:10:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h124-renewed-near-term-focus-on-pharma-services/ 2025-10-30T10:10:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/scaling-the-business-to-drive-continued-momentum/ 2025-10-30T10:10:11+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/gathering-momentum-in-pharma-services/ 2025-10-30T10:10:15+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/building-content-to-drive-widespread-adoption/ 2025-10-30T10:10:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/moving-in-the-right-direction-to-capture-growth/ 2025-10-30T10:10:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/revenue-building-and-growth-opportunities-are-developing/ 2025-10-30T10:10:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/recent-deals-provide-evidence-of-assay-traction/ 2025-10-30T10:10:34+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/pursuing-a-multi-faceted-parsortix-commercial-opportunity/ 2025-10-30T10:10:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy22-a-year-of-two-very-distinct-halves/ 2025-10-30T10:10:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/post-fda-approval-commercial-mometum-is-building/ 2025-10-30T10:10:48+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/20m-raise-funds-commercialisation-through-to-mid-24/ 2025-10-30T10:10:53+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/parsortix-fda-clearance-marks-a-key-transition-point/ 2025-10-30T10:11:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy21-results-prepared-for-commercial-success/ 2025-10-30T10:11:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fda-approval-awaited-ldt-data-expected-h122/ 2025-10-30T10:11:10+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/looking-ahead-to-the-next-chapter/ 2025-11-10T15:43:25+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/advancing-innovation-and-increasing-core-business-focus/ 2025-11-10T15:44:05+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/flow-of-catalysts-continues-with-more-into-2025/ 2025-11-10T15:44:43+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/data-at-eha-2024-heighten-focus-on-sovleplenib/ 2025-11-10T15:45:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/executing-consistently-on-the-road-to-breakeven/ 2025-11-10T15:45:51+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/surfing-the-waves-towards-profitability/ 2025-11-10T15:46:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/asco-2023-a-growing-body-of-evidence-for-fruquintinib/ 2025-11-10T15:47:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/significant-2022-achievements-catalyse-a-promising-2023/ 2025-11-10T15:47:41+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fresco-2-data-support-broad-uptake-in-later-line-mcrc/ 2025-11-10T15:48:13+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/rich-and-diverse-pipeline-with-multiple-waves-of-growth/ 2025-11-10T15:48:50+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/on-the-right-track/ 2025-11-10T15:49:19+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/abundant-development-opportunities-in-immuno-oncology/ 2025-11-17T07:22:27+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/latest-scope-data-confirm-durable-improvement/ 2025-12-09T07:40:16+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/pipeline-potential-underpins-long-term-growth-prospects/ 2025-12-15T07:46:00+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy25-results-delivering-despite-the-challenges/ 2025-12-16T07:23:02+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fap-dox-phase-ib-results-confirm-efficacy-in-sgc/ 2025-12-18T09:13:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/a-month-of-notable-pipeline-progress/ 2026-01-09T07:22:31+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/precision-prospects-build/ 2026-01-21T07:15:44+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fda-clears-global-phase-iii-trial-for-iscib1/ 2026-01-26T08:15:23+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/innovative-ai-analysis-comparing-precision-pdcs-to-adcs/ 2026-02-24T07:11:59+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/momentum-in-revenues-attc-development-promise/ 2026-03-06T08:40:13+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/10m-raise-extends-runway-beyond-fap-exd-catalysts/ 2026-03-27T07:44:29+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/fy25-results-clinical-data-will-define-the-coming-year/ 2026-05-20T06:12:21+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/raise-of-9m-pays-down-convertible-bond-to-c-11-5m/ 2026-06-08T06:02:45+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/attc-data-confirms-clinical-potential/ 2026-06-09T12:45:30+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/iscib1-pivotal-trial-plans-advancing/ 2026-06-22T06:48:06+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h126-solid-iscib1-data-underpins-planned-progress/ 2026-06-26T16:44:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/ava6103-fap-exd-starts-phase-ia-focus-clinical-trial/ 2026-06-26T17:19:49+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h126-encouraging-progress-but-challenges-remain/ 2026-07-01T06:33:39+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/tumour-activated-drug-delivery-demonstrated/ 2026-07-07T08:11:40+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/strategic-transactions-to-unlock-longer-term-value/ 2026-07-23T10:06:15+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/h126-china-recovery-and-fruzaqla-drive-sales-growth/ 2026-07-31T11:24:20+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg https://www.trinitydelta.org/research-notes/saffron-data-positions-savo-combo-competitively/ 2026-08-18T16:03:18+00:00 https://www.trinitydelta.org/wp-content/uploads/2018/01/stem-cells-blue-e1490947064490.jpg